India's pharmaceutical firms reported strong earnings growth for the June-ended quarter, led by higher sales of drugs for chronic ailments and strong business for the API segment. The outlook for coming quarters remains positive, though margins might ease
(This story appears in the 11 September, 2020 issue of Forbes India. To visit our Archives, click here.)